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ABSTRACT
Objective The aim of this study was to determine the
prevalence of vitreoretinal interface abnormalities
(VRIA), the degree of visual impairment and
associations with VRIA among adults, aged 40–69
years, in the UK Biobank study.
Methods and analysis Colour fundus photographs
and spectral domain optical coherence tomography
images were graded for 25% of the 8359 UK Biobank
participants with mild visual impairment or worse
(LogMAR >0.3 or Snellen <6/12) in at least one eye.
The prevalence and contribution of VRIA to visual
impairment was determined and multinomial logistic
regression models were used to investigate association
with known risk factors and other predetermined
socioeconomic, biometric, lifestyle and medical
variables for cases and matched controls.
Results The minimum prevalence of any VRIA was
17.6% and 8.1% in the eyes with and without visual
impairment, respectively. VRIA were identified as the
primary cause of visual impairment in 3.6% of eyes.
Although epiretinal membrane and vitreomacular
traction were the most common VRIA, the degree of
visual impairment was typically milder with these than
with other VRIA. Visual impairment with a VRIA was
positively associated with increasing age (relative risk
ratio (RRR) 1.22 (95% CI 1.07 to 1.40)), female
gender (RRR 1.28; 1.08 to 1.52) and Asian or Asian
British ethnicity (RRR 1.60; 1.10 to 2.32).
Conclusions VRIA are common in middle-aged
adults in the UK Biobank study, especially in eyes with
visual impairment. VRIA were considered to be the
primary cause of visual impairment in 3.6% of all eyes
with visual impairment, although there was variation in
the degree of visual impairment for each type of VRIA.
INTRODUCTION
Despite the widespread use of spectral
domain optical coherence tomography
(OCT) in routine clinical practice, there is
limited data on the prevalence and visual
consequences of different vitreoretinal
interface abnormalities (VRIA). Much of the
existing epidemiological data are derived
from slit-lamp examination, either alone or
in combination with grading of colour
fundus photographs, but several VRIA are
not readily identifiable using these
techniques.
Key messages
What is already known?
" Several population-based studies have reported
the prevalence of posterior vitreous detachment
and vitreoretinal interface abnormalities (VRIA)
and the association of VRIA with visual
impairment.
What are the main findings?
" In this study with UK Biobank participants,
VRIA were common abnormalities, both in eyes
with and without visual impairment, and were
identified at least four times more often with
spectral domain optical coherence tomography
(OCT) imaging than with colour fundus
photography. Visual impairment due to VRIA
was typically mild or moderate and the most
common VRIA were epiretinal membrane and
vitreomacular traction. Visual impairment in
one or both eyes and a VRIA was positively
associated with increasing age, female gender
and Asian or Asian British ethnicity.
How might these results change the focus of
research or clinical practice?
" VRIA are common abnormalities, even when
the prevalence of other retinal pathology is low.
The size of the UK Biobank project may provide
additional opportunities to identify novel
associations with VRIA. Spectral domain OCT
imaging should be used in any future
epidemiological studies documenting the
prevalence of VRIA.
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Table 1 Baseline characteristics of the cases and controls
Baseline characteristic
Controls without visual
impairment (n=7704)
Cases with visual impairment but
without VRIA (n=1671)
Cases with visual
impairment and VRIA (n=419)
Age, median (IQR) 61 (54–65) 61 (54–65) 61 (55–66)
Sex
Female, n (%) 4288 (55.7) 956 (57.2) 206 (49.2)
Male, n (%) 3416 (44.3) 715 (42.8) 213 (50.8)
Ethnicity
White, n (%) 6881 (89.9) 1503 (90.5) 364 (87.5)
Asian or Asian British, n
(%)
257 (3.4) 49 (3.0) 22 (5.3)
Black or Black British, n
(%)
374 (4.9) 73 (4.4) 22 (5.3)
Other ethnic group, n
(%)
142 (1.9) 36 (2.2) 8 (1.9)
Townsend deprivation
index quintiles
First—least deprived 1304 (16.9) 227 (13.6) 63 (15.1)
Second 1474 (19.2) 280 (16.8) 70 (16.7)
Third 1501 (19.5) 335 (20.1) 87 (20.8)
Fourth 1763 (22.9) 377 (22.6) 103 (24.6)
Fifth—most deprived 1653 (21.5) 448 (26.9) 95 (22.7)
Blood pressure
diastolic, median (IQR)
82 (75–89) 82 (75–89) 82 (75–88)
Blood pressure systolic,
median (IQR)
141 (128–154) 140 (127–154) 142 (129–155)
Body mass index
category
Normal/Underweight, n
(%)
2366 (31.8) 521 (32.3) 132 (32.1)
Overweight, n (%) 3251 (43.7) 678 (42.0) 171 (41.6)
Obese, n (%) 1816 (24.4) 416 (25.8) 108 (26.3)
Whole body
impedance, median
(IQR)
595 (534–664) 598 (539–667) 583 (527–652)
Waist:hip ratio, median
(IQR)
0.88 (0.81–0.94) 0.88 (0.81–0.94) 0.89 (0.82–0.95)
Pulse wave arterial
stiffness index, median
(IQR)
9.34 (7.26–11.37) 9.28 (7.2–11.24) 9.82 (7.46–11.54)
Current smoking status
No, n (%) 6989 (91.0) 1485 (88.9) 374 (89.3)
Yes, n (%) 485 (6.3) 143 (8.6) 32 (7.6)
Occasionally, n (%) 203 (2.6) 42 (2.5) 13 (3.1)
Continued
2 McKibbin M, et al. BMJ Open Ophth 2017;1:e000057. doi:10.1136/bmjophth-2016-000057
Open Access
group.bmj.com on January 31, 2018 - Published by http://bmjophth.bmj.com/Downloaded from 
The UK Biobank study aims to investigate the influ-
ence of lifestyle, environment and genes on the health
of adults, aged 40–69 years, in the UK.1 The study
recruited more than 500 000 UK residents and
provides a unique opportunity to collect accurate data
on the frequency and causes of visual impairment
among participants. We have already identified that
VRIA were the fourth most common cause of identifi-
able visual impairment among UK Biobank
participants.2 In this paper, we report the prevalence
and visual consequences of different types of VRIA,
both in eyes with and without visual impairment and
investigate associations with VRIA within the UK
Biobank cohort.
METHODS
Study design and population
All UK Biobank participants completed a baseline
assessment that comprised a questionnaire, with health
and disease questions, followed by recording of physical
measurements and collection of biological samples. Eye
health questions and physical measures were added
several years after the start of the study and included
visual acuity with habitual correction using a computer-
ised, semiautomated system using LogMAR optotypes,
refractive error, intraocular pressure and corneal
biomechanics. Digital fundus photography and spectral
domain OCT images were taken on both eyes using the
Topcon 3D-OCT 1000 Mark 2. A single non-mydriatic,
45 digital, colour image, centred on the fovea and a
spectral domain OCT cube scan of the macula, covering
a 6mm6mm retinal area (128 horizontal line scans
comprised of 512 A-scans), were captured for both eyes.
Baseline visual acuity, refraction, corneal biome-
chanics and intraocular pressure (IOP) data were
recorded for 133 668 participants and, from this
cohort, colour fundus photographs and spectral
domain OCT images were also captured in 65 033
participants. For these participants with fundus and
OCT images, 8359 were identified as having mild
visual impairment or worse (LogMAR >0.3 or
Snellen<6/12) in at least one eye. In this pilot
study, the ability to identify both the primary cause
of and associations with visual impairment, using
self-reported eye history and image grading, was
investigated in a subset of 25% of those with visual
impairment and fundus imaging. Cases were selected
to be representative of all participants with visual
impairment in terms of visual acuity, age (5-year
bands), sex and ethnicity (Asian, Black, Mixed, White
or other background). Controls did not have visual
impairment but were matched for the cases by age,
sex and ethnicity at a ratio of approximately 4:1.
The UK Biobank project received approval from the
North-West Multicentre Research Ethics Committee.
Approval was also obtained for access to anonymised
UK Biobank data by researchers, without the need for
additional approvals.
Image grading and definitions
Images were analysed using the Topcon OCT viewer
software (V.4.21, Topcon, Tokyo, Japan) and graded
by clinicians or experienced, non-medical graders.
Analysis involved all of the eyes with visual
impairment and some of the fellow, non-impaired
eyes of consecutive cases with monocular visual
impairment. Fundus photographs were assessed for
image quality, media opacity, optic disc or retinal
vascular or other abnormalities and the presence of
signs of age-related maculopathy. SD OCT images
were assessed for image quality, VRIA
and intraretinal abnormalities. Fundus photographs
Table 1 Continued
Baseline characteristic
Controls without visual
impairment (n=7704)
Cases with visual impairment but
without VRIA (n=1671)
Cases with visual
impairment and VRIA (n=419)
Medications
Systemic hypertension,
n (%)
1804 (23.6) 405 (24.5) 107 (25.8)
Hypercholesterolaemia,
n (%)
1597 (20.9) 367 (22.2) 107 (25.8)
Medical history
Cancer, n (%) 806 (10.5) 173 (10.4) 42 (10.0)
Diabetes mellitus, n (%) 458 (7.7) 114 (8.6) 42 (11.8)
Cardiovascular and/or
cerebrovascular
disease, n (%)
2431 (40.8) 544 (40.9) 151 (42.4)
Depression: n (%) 392 (6.6) 79 (5.9) 19 (5.3)
VRIA, vitreoretinal interface abnormalities.
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were considered to be ungradeable when either the
fovea or the optic disc or more than 33% of the
total image was not visible. OCT images were consid-
ered to be ungradeable when severe artefacts were
present or the signal strength was reduced across the
image set to the extent that major interfaces could
not be clearly identified. The senior clinician
supported the other graders whenever there was any
uncertainty about the grading outcome and repeated
the grading of 2.5% of the images (80% abnormal
and 20% normal) for quality assurance purposes.
The decision of the senior clinician was adopted in
any disputed cases.
For the presence or absence of VRIA, standard defi-
nitions were used for the following abnormalities:
vitreomacular traction (VMT), epiretinal membrane
(ERM) either alone or in combination with intraretinal
cysts and other abnormalities, lamellar or partial-thick-
ness macular hole (PTMH), full-thickness macular hole
(FTMH) and foveoschisis.3 4
Using the self-reported eye history and the image
grading outcomes, graders were asked to identify the
primary cause of visual impairment, taking account of
the level of visual impairment. Unless a single
pathology was sufficient to explain all or the majority
of the recorded level of visual acuity, no primary cause
of visual impairment was recorded.
Table 2 Overall prevalence of VRIA on image grading of colour fundus photographs and OCT images
Monocular visual
impairment eyes
(n=1684)
Binocular visual
impairment eyes
(n=812)
No visual
impairment eyes
(n=472)
Colour fundus
images
Gradeable images 1 362 645 385
ERM 64 (4.7%*) 24 (3.72%*) 7 (1.82%*)
FTMH 2 (0.15%*) 0 0
Spectral
domain OCT
images
Gradeable images 1 615 775 464
VMT at fovea 14 (0.87%*) 12 (1.55%*) 3 (0.65%*)
VMT elsewhere 10 (0.62%*) 8 (1.03%*) 3 (0.65%*)
ERM at fovea 50 (3.1%*) 22 (2.84%*) 5 (1.08%*)
ERM elsewhere 274 (16.96%*) 125 (16.13%*) 31 (6.68%*)
FTMH 3 (0.19%*) 2 (0.26%) 0
PTMH 12 (0.74%*) 3 (0.39%*) 5 (1.08%*)
Foveoschisis 5 (0.31%) 3 (0.39%*) 0
*Of gradeable images.
ERM, epiretinal membrane; FTMH, full-thickness macular hole; OCT, optical coherence tomography; VMT, vitreomacular traction; VRIA,
vitreoretinal interface abnormalities.
Table 3 Relative contribution of VRIA to each category of visual impairment
Visual impairment category
Monocular visual
impairment, n (%*)
Binocular visual
impairment-better seeing
eye, n (%*)
Binocular visual
impairment-worse seeing
eye, n (%*)
Mild (LogMAR>0.3–<0.45) 29 (3.2) 10 (3.8) 2 (2.4)
Moderate (LogMAR 0.45–<1.0) 29 (4.2) 2 (1.5) 12 (4.1)
Severe (LogMAR 1.0–<1.3) 2 (2.3) 0 2 (8.0)
Blindness (LogMAR>1.3) 0 0 1 (16.7)
Total 60 12 17
*Of all the eyes with that level of visual impairment.
VRIA, vitreoretinal interface abnormalities.
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Statistical analysis
Descriptive statistics were used to report the prevalence
of VRIA in the UK Biobank participants and the contri-
bution of both any and each type of VRIA to the visual
impairment categories. The characteristics of the cases
with visual impairment, both without and with VRIA,
were also compared with the controls using descriptive
statistics. Univariate multinomial logistic regression
models were used to investigate the association between
known risk factors and other predetermined socioeco-
nomic, biometric, lifestyle and medical variables and
visual impairment, both without and with VRIA,
compared with the matched controls. Those factors
found to be associated with visual impairment at a 10%
level (to account for potential correlation between
factors) were then included in a multivariable multino-
mial logistic regression model. Only those that were
significantly associated (p<0.05) with visual impairment
remained in the final multivariable model. Although the
cases and controls were matched by age, sex and ethnic
group, it is recommended also to adjust for these varia-
bles to account for any remaining differences, therefore
the final multivariable models included these variables
irrespective of their association with visual impairment.5
The final multivariable model was checked for collin-
earity (r>0.7 and p<0.05) between variables included in
the model, and no evidence was found.
RESULTS
In this pilot study, colour fundus photographs and
spectral domain OCT images were reviewed for 2090
UK Biobank participants, of whom 1684 had monoc-
ular visual impairment and 406 had binocular visual
impairment.
Image quality
Image grading for the presence of VRIA in the 2496
eyes with visual impairment was not possible due to
image quality for 489 (19.6%) colour fundus photo-
graphs and 106 (4.2%) OCT scans.
For the 472 eyes without visual impairment but
included in the analysis, image grading was not
possible for 87 (18.4%) colour fundus photographs and
8 (1.7%) OCT scans.
Prevalence and types of VRIA
Of the 2090 UK Biobank participants included in this
pilot study, VRIA were present in one or both eyes of
419 (20.0%) participants. The baseline characteristics of
the cases with and without VRIA and controls are shown
in table 1. At least one VRIA was identified in 444 of
2496 eyes (17.6%) with visual impairment of any cause
and in 38 of 472 eyes (8.1%) without visual impairment.
For the eyes with gradeable images, at least one
VRIA was identified in 88 (4.4%) eyes with visual
impairment and 7 (1.8%) eyes without visual
impairment using colour fundus photography. With
OCT imaging, any VRIA was identified in 444
(22.1%) of eyes with visual impairment and 38
(8.2%) of eyes without visual impairment. All the
VRIA identified using colour fundus photography
were also identified on OCT imaging and none were
identified on colour fundus photography alone.
Many eyes had more than one type of VRIA,
including 99 of the eyes with visual impairment and
9 of those without. Additional retinal pathology, such
as evidence of diabetic retinopathy or age-related
maculopathy, was seen in 88 (18.7%) eyes with VRIA
and visual impairment and in 97 (20.7%) of the eyes
with VRIA but no visual impairment.
ERM was the most common individual VRIA on both
colour fundus photography and OCT imaging. Both
FTMH and ERM were identified at least three times
more often on OCT imaging than on colour fundus
photography. Apart from FTMH, all VRIA were identi-
fied in both the eyes with visual impairment and in the
eyes without visual impairment, according to the defi-
nition used in this study. Only PTMH was more
common in the eyes without visual impairment. The
relative frequency of each VRIA, for all gradeable
images but regardless of the cause of visual
impairment, is shown in table 2.
Table 4 Level of visual impairment associated with each of the main VRIA in the 89 eyes with VRIA as the primary cause
of visual impairment
Visual impairment category
Epiretinal
membrane Foveoschisis
Full-thickness
macular hole
Partial-thickness
macular hole
Vitreomacular
traction
Mild (LogMAR >0.3–<0.45) 26 4 0 3 8
Moderate (LogMAR 0.45–<1.0) 26 2 4 4 7
Severe (LogMAR 1.0–<1.3) 1 1 1 1 0
Blindness (LogMAR>1.3) 0 1 0 0 0
Total 53 8 5 8 15
VRIA, vitreoretinal interface abnormalities.
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For the five FTMHs identified on OCT imaging,
the mean, minimum width on OCT imaging was
530mm, with one being small in size (<250mm) and
four being large (more than 400mm). All cases of
VMT causing visual impairment would be classified
as focal (maximum width <1500 mm), with a mean
VMT width of 367mm.
Relative contribution of VRIA to visual impairment
VRIA were identified as the most likely, primary cause
of visual impairment in 89 eyes (3.6%) of 83 partici-
pants (4.0%) participants. This included 60 (3.6%) eyes
of participants with monocular visual impairment and
12 (3.0%) and 17 (4.2%) of the better and worse-seeing
eyes, respectively, of participants with binocular visual
impairment. The relative contribution of VRIA to each
category of visual impairment for all 2090 cases is
shown in table 3.
Main VRIA causing visual impairment
ERM and VMT were the most common primary diag-
noses leading to visual impairment in 53 (58.9%) and 15
(16.7%) of the eyes with VRIA, respectively. The degree
of visual impairment was typically milder for both ERM
and VMT than for the other VRIA leading to visual
impairment. Mean LogMAR acuity in the eyes with
visual impairment due to VRIA was 0.53 (range 0.32–
1.2) for ERM, 0.46 (0.32–0.64) for VMT, 0.58 (0.34–1.0)
for PTMH, 0.7 (0.32–1.3) for foveoschisis and 0.82
(0.64–1.25) for FTMH. The categories of visual
impairment for each VRIA diagnosis are given in table 4.
Although the number of eyes without visual
impairment but with a VRIA was small, 13 eyes had a
central VRIA that had the potential to affect visual
acuity. Mean LogMAR acuity was 0.02 (range  0.08 to
0.10) for the three eyes with VMT involving the fovea,
0.10 (range  0.02 to 0.24) for the five eyes with ERM
involving the fovea and 0.10 (range  0.06 to 0.22) for
the five eyes with PTMH.
Associations with VRIA
Compared with the controls without visual impairment,
age, gender, ethnicity, deprivation, whole body imped-
ance, waist:hip ratio, current smoking status,
cholesterol medications and those with diabetes were
individually significantly associated (at 5% level) with
visual impairment, either with or without VRIA. On
inclusion in a multivariable model, only age, gender,
ethnicity and deprivation remained significantly associ-
ated with visual impairment. For the cases with visual
impairment, the presence of VRIA was positively asso-
ciated with increasing age (relative risk ratio (RRR)
1.22; 95%CI 1.07 to 1.40), female sex (RRR 1.28;
1.08 to 1.52) and Asian ethnicity (1.60; 1.10 to 2.32).
These associations were not seen in the cases with
visual impairment but without VRIA. Compared with
controls, visual impairment but without VRIA wasT
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negatively associated with female sex (RRR 0.94;
0.90 to 0.98), Asian ethnicity (RRR 0.83; 0.71 to 0.97)
and Black ethnicity (RRR 0.79; 0.69 to 0.90) and posi-
tively associated with increasing deprivation (RRR
1.59; 1.33 to 1.91 for the most deprived quintile). Asso-
ciations between predetermined risk factors or
potential, novel associations and VRIA with visual
impairment are shown in table 5.
DISCUSSION
Among UK Biobank participants with visual
impairment, VRIA were identified as the most likely,
primary cause of visual impairment in 3.6% of eyes,
and the prevalence of any VRIA was 17.6% in the eyes
with visual impairment and 8.1% of the eyes without
visual impairment.
The overall prevalence of VRIA in this study, for the
eyes with and without visual impairment, is comparable
to other studies. In the population-based Beijing Eye
Study, the prevalence of ERM was 2.2% per eye, based
on grading of fundus photographs alone.6 In other
population-based studies and using a combination of
fundus photographs and slit-lamp examination, Miya-
zaki et al7 and McCarty et al8 reported ERM prevalence
figures of 4.0% and 6%, respectively. With time domain
OCT and fundus photography, the Handan Eye Study
recorded a prevalence of 3.4% for ERM alone.9 With
the benefit of spectral domain OCT, Fusi-Rubiano
et al
10 reviewed the OCT images from consecutive
patients attending a retina clinic and reported a preva-
lence of 7.3% for any VRIA. However, almost 40% of
the cases in that series had vitreomacular adhesion
alone. In an urban Chinese population, Liu et al11
reported a prevalence of 16.8% for any VRIA among
adults without eye disease, excluding eyes with poste-
rior vitreous detachment alone. Meuer et al12 reported
a prevalence of 39.7% for any VRIA, excluding
macular and paravascular cysts, among the residents of
Beaver Dam.
Differences between the VRIA prevalence reported
here and other published series are likely to be the
result of differing VRIA definitions, methods of ascer-
tainment of pathology and the population
characteristics. In keeping with more recent studies
that used spectral domain OCT imaging, this study
included a variety of subtypes of VRIA. As reported in
the Beaver Dam study, the data presented here illus-
trates the superiority of spectral domain OCT over
fundus photography in identifying both ERM and
FTMH.12 Other VRIA, such as VMT and foveoschisis,
would not be expected to be identifiable on colour
fundus photography. Several studies have shown that
the prevalence of ERM and other VRIA increases with
age, the presence of other retinal pathology, prior cata-
ract surgery and myopia.7 9 11 12 In this study of UK
Biobank participants, the prevalence of VRIA in the
eyes with visual impairment was at least twice that in
the eyes without. The mean age of the participants
studied here was 61 years, compared with 74 years in
the Beaver Dam study, and other retinal disease was
identified in over 20% of the eyes with visual
impairment and a VRIA.
Among UK Biobank participants, ERM and VMT
were the most common VRIA causing visual
impairment, but the visual acuity with these abnormali-
ties was typically better than for partial or full-thickness
macular holes and foveoschisis. Fusi-Rubiano et al10
reported a decrease in visual acuity as the grade of
VRIA changed from VMT to FTMH. The same study
also identified that many eyes with VMT did not have
visual impairment. The data presented in this article
illustrate that VRIA were more common in the eyes
with visual impairment but were also present in 8% of
the eyes without visual impairment, using the predeter-
mined LogMAR acuity >0.3 to define visual
impairment. Mean visual acuity in the eyes in the
Beaver Dam study with both epiretinal membrane and
partial-thickness macular hole was better than this
threshold.12 Similarly, in the series reported by Fusi-
Rubiano et al, the majority of eyes with VMT retained
good visual acuity and there was a large range of visual
acuities recorded for each VRIA, with the possible
exception of FTMH.10 Some of the eyes with VRIA in
the UK Biobank also had visual acuity levels better
than LogMAR 0.3 but worse than LogMAR 0.0.
Increasing age, female sex and Asian ethnicity were
significant associations with visual impairment and
VRIA among UK Biobank participants using multivari-
able analysis, even though cases and controls were
matched by age, sex and ethnicity. With each addi-
tional decade, the prevalence of VRIA was 22% greater
for the cases with a VRIA in one or both eyes than for
the controls without visual impairment. For female
cases with VRIA, the prevalence of VRIA was 28%
greater than for the controls. The associations of VRIA
with increasing age and female sex have been reported
before and are likely to reflect the trend for detach-
ment of the posterior hyaloid with increasing age and
female sex.9 11 13 The association with Asian ethnicity,
but not other ethnic minority status, may be a conse-
quence of the high prevalence of myopia in this
group.9 14 No association was seen with other variables,
including serum cholesterol, diabetes mellitus and
smoking status, that have previously been reported as
being positively associated with a range of VRIA.7 11
However, medication for cholesterol, diabetes mellitus
and smoking status were found to be associated with
visual impairment at the 5% level on univariate analysis
and were included in the initial multivariable model.
The image quality of the colour fundus photographs
reviewed for this study was variable but the quality of
the OCT images was much better, with only 3.7% of all
the OCT images judged to be ungradeable. By
comparison, in the Beaver Dam study, OCT images
from 9% of eyes were excluded because the image was
either missing or ungradeable.12 In the Beijing Eye
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study, 5.5% of OCT images were felt to be of insuffi-
cient quality for grading.15
This pilot study has a number of strengths and
potential weaknesses. The UK Biobank was one of the
first to use spectral domain OCT imaging and over
65 000 participants met the criteria for inclusion in this
study. Many of the key findings in relation to the prev-
alence of VRIA and the level of associated visual
impairment are consistent with other studies. Images
were graded by experienced clinicians and graders.
Although there must be some uncertainty about the
identification of VRIA as the primary cause of visual
impairment, the deformation of the retinal architecture
was greater in the eyes with VRIA identified as the
primary cause than in the eyes with VRIA as an inci-
dental finding. Furthermore, the degree of visual
impairment was typically mild or moderate for most
VRIA and especially for VMT and ERM. However, the
UK Biobank study is not a population-based study and
the response rate to the invitation to participate was
low.1 Participants were generally healthier, older, more
affluent and more likely to be urban than the full UK
population and so may not be representative.14 16 As a
result, the prevalence figures reported here may not be
applicable to the wider UK population and are likely to
be minimum estimates.17 This pilot study involved
image grading for a representative sample of only 25%
of the participants with visual impairment and not all
of the fellow eyes without visual impairment were
included. The lack of association with other previously
reported variables on multivariable analysis may also
suggest that this study was underpowered. The preva-
lence of VRIA in the control population without visual
impairment is also not known.
VRIA are common findings in middle-aged adults in
the UK Biobank study, both in eyes with and without
mild visual impairment or worse, and many eyes have
more than one interface abnormality. VRIA were iden-
tified as the most likely, primary cause of visual
impairment in 3.6% of eyes, with ERM and VMT the
most common diagnoses leading to visual impairment.
Visual impairment with VRIA was positively associated
with increasing age, female sex and Asian or Asian
British ethnicity.
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